Leerink Partners reiterated their market perform rating on shares of 2seventy bio (NASDAQ:TSVT – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage ...
Dealbreaker on MSN6h
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M DealMultiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...
Lifeworks Advisors LLC increased its stake in Regeneron Pharmaceuticals by 31.5%, now holding 6,743 shares worth $4.8 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback